Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Japan Biosimilars Markets 2017 - The Start of Authorized Biosimilar Era? - Research and Markets

Research and Markets
Posted on: 22 Aug 17

The "Japan Biosimilars - The Start of Authorized Biosimilar Era?" report has been added to Research and Markets' offering.

In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, and current trend of biosimilars use in Japan. It also details Japanese Chuikyo (Central and Social Regulatory Council) stand for Biosimilar penetration and regulatory approval requirement for non- JP specific dosage strength or/has clinical data from Ex-Japan clinical trial.

The report provide all the Japanese/Global players' activities in biosimilar space for Japan market along with their pipeline deal history, current Mab tech platforms, alliances and deal structure. It details crisp summary on strategies of each key player (-36 JP local companies, multinational companies), their interest & focus for future collaboration in biosimilar space.

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Japanese Government And Chuikyo Initiatives To Increase Biosimilar Penetration In Japan- In Line With Recent Honebuto

Chapter 3: Growth Hormone & Erythropoietin- Lessons From Launched Biogeneric Progress In Japan Since 2009

Chapter 4: Filgrastim (Gran) Bs: Now Focus Shift To Pegfilgrastim Bs Development- Possibility Of KhkS Ag Of G-Lasta- A Blow For Other Players?

Chapter 5: Remicade BS - Nichi Iko Remicade BS Launch By Ye2017- Will Help In To Remicade Bs Overall Penetration Including Remicade Bs Nippon Kayaku

Chapter 6: Lantus Biosimilar- One Of The Most Successful Bs Launch In Japan- Competition Intensify After Fujifilm Biocon Lantus Bs Launch In 2016

Chapters 7: Next Wave Of Biosimilar Opportunities In Japan

Chapter 8 Biosimilar/Biopharma CMO Opportunity

Chapter 9 Regulatory Approval Requirement For Complex Mab Biosimilar In Japan

Chapter 10: Licensing/Consolidation Activities In Biosimilar Space In Japan

Companies Mentioned

  • Amgen
  • Asahi Glass
  • Aska Pharmaceuticals
  • Chugai Pharmaceuticals
  • Daiichi Sankyo
  • Fuji Film Kyowa Kiri
  • Fuji Pharma
  • Gene Techno Science
  • Itochu Chemical Fron
  • JCR Pharmaceuticals
  • Kissei
  • Kyowa Hakko Kirin
  • MGC Pharma
  • Meiji Seika Pharma
  • Mitsubishi Tanabe
  • Mochida
  • Nichi-Iko
  • Nippon Kayaku
  • Nipro Pharma
  • Sanwa Kagaku
  • Sawai
  • Takeda Teva Pharmacy
  • Towa
  • Toyobo Biologics
  • UMN Pharma
  • Yoshindo

For more information about this report visit

View source version on

Business Wire

Last updated on: 22/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.